home / stock / otlkw / otlkw news

OTLKW News and Press, Outlook Therapeutics Inc. Series A Warrant From 05/15/20

Stock Information
Company Name: Outlook Therapeutics Inc. Series A Warrant
Stock Symbol: OTLKW
Market: NASDAQ
Website: outlooktherapeutics.com
Menu
OTLKW OTLKW Quote OTLKW Short OTLKW News OTLKW Articles OTLKW Message Board
Get OTLKW Alerts

News, Short Squeeze, Breakout and More Instantly...
OTLKW - Outlook Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2020 and Provides Corporate Update

Company remains on track to report topline data results from NORSE 1, its first registration clinical trial evaluating ONS-5010, an investigational ophthalmic formulation of bevacizumab to treat wet AMD, in August 2020   Enrollment in NORSE 2 registration clinical trial remains on...
OTLKW - Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors

Internationally renowned ophthalmologist, Gerd Auffarth, MD, ranked as one of the “100 most influential personalities in ophthalmology worldwide" in the 2020 Power List published by The Ophthalmologist  magazine Julian Gangolli, former President of the North American...

OTLKW - Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit

CRANBURY, N.J., April 15, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use...

OTLKW - Outlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2

Company reports no anticipated COVID-19 impact on NORSE 1, its first registration clinical trial evaluating ONS-5010, an investigational ophthalmic formulation of bevacizumab, to treat wet AMD   Risk mitigation strategies being developed for possible one- to three-month delay re...
OTLKW - Outlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-Market

CRANBURY, N.J., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in ret...

OTLKW - Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market

CRANBURY, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in ret...

OTLKW - Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020

CRANBURY, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in r...
OTLKW - Outlook Therapeutics to Present at the 2020 BIO CEO & Investor Conference

CRANBURY, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”),  a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for us...

OTLKW - Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010

CRANBURY, N.J., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in r...

OTLKW - Outlook Therapeutics Announces Completion of Warrant Restructuring

CRANBURY, N.J., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in r...
Previous 10 Next 10